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INTRODUCTION 
 
GASTRO RETENTIVE DRUG DELIVERY SYSTEM 
Gastro retentive system can remain in the gastric region for several hours and 
hence significantly prolong the gastric residence time of drugs. Prolonged gastric 
retention improves bioavailability, reduces drug waste, and improves solubility for 
drugs that are less soluble in high pH environment. It has applications also for local 
drug delivery to the stomach and proximal small intestine. Gastro retention helps to 
provide better availability of new products with new therapeutic possibilities and 
substantial benefits for patients. 
The controlled gastric retention of solid dosage forms may be achieved by the 
mechanisms of mucoadhesive [Ponchel G and Irache JM, 1998; Shweta Arora, et.al. 
2005], flotation [Deshpande A, et.al. 1997], sedimentation [Rednick AB and Tucker 
SJ, 1970; Davis SS, et.al. 1986], expansion [Urguhart J and Theeuwes F, 1994; 
Mamajek RC and Moyer ES, 1980], modified shape system [Fix JA, et. al. 1993; 
Kedzierewicz F, et.al. 1999] or by the simultaneous administration of 
pharmacological agents [Groning R and Heun, 1984; 1989] that delay gastric 
emptying. 
Floating drug delivery system is also referred as Hydrodynamically Balanced 
System (HBS) or Gastro Retentive Drug Delivery System (GRDDS). 
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FACTORS AFFECTING GASTRIC RETENTION 
Gastric residence time of an oral dosage form is affected by several factors.  
1. Gastric pH 
The pH of the stomach in fasting state is 1.5 to 2.0 and in fed state is 2.0 to 
6.0. A large volume of water administered with an oral dosage form raises the pH of 
stomach contents 6.0 to 9.0. 
2. Formulation factor 
2.1 Pattern or nature of the dosage form 
Several formulation parameters can affect the gastric residence time. More 
reliable gastric emptying patterns are observed for multi-particulate formulations as 
compared with single unit formulation. [Bechgaard H and Ladefoged K, 1978]  
2.2 Size and shape of dosage form 
Size and shape of dosage form also affect the gastric emptying. Garg and 
Sharma [Garg S and Sharma S, 2003] reported that tetrahedron and ring-shaped 
devices have a better gastric residence time as compared with other shapes. The 
diameter of the dosage unit is also equally important as a formulation parameter. 
Dosage forms having a diameter of more than 7.5 mm show a better gastric residence 
time compared with one having 9.9 mm.  
2.3 Density of the dosage form  
The density of the dosage form also affects the gastric emptying rate. A 
buoyant dosage form having a density of less than that of the gastric fluids floats. 
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Since it is away from the pyloric sphincter, the dosage unit is retained in the stomach 
for a prolonged period. [Shweta Arora, et.al. 2005] 
3. Food intake 
A comparison was made to study the affect of fed and non fed stages on 
gastric emptying. For this study all subjects remaining in an upright position were 
given a light breakfast and another similar group was fed with a succession of meals 
given at normal time intervals. It was concluded that as meals were given at the time 
when the previous digestive phase had not completed, the floating form buoyant in 
the stomach could retain its position for another digestive phase as it was carried by 
the peristaltic waves in the upper part of the stomach. [Shweta Arora, et.al. 2005] 
4. Fluid volume 
The resting volume of the stomach is 25 to 50 ml. Volume of liquids 
administered affects the gastric emptying time. When volume is large, the emptying is 
faster. Fluids taken at body temperature leave the stomach faster than colder or 
warmer fluids. [Shweta Arora, et.al. 2005] 
5. Biological factors 
Biological factors such as age, body mass index (BMI), gender, posture, and 
diseased states (diabetes) influence gastric emptying. In the case of elderly persons, 
gastric emptying is slowed down. Generally females have slower gastric emptying 
rates than males. Stress increases gastric emptying rates while depression slows it 
down. [Singh BN and Kim KH, 2000]  
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CLASSIFICATION OF FLOATING DRUG DELIVERY SYSTEM 
Floating Drug Delivery Systems are classified depending on the use of two 
formulation variables. They are Effervescent and Non-effervescent systems. 
EFFERVESCENT FLOATING DOSAGE FORM 
These are matrix type of system prepared with the help of swellable polymers 
such as Methyl cellulose and various effervescent compounds e.g. Sodium carbonate, 
Tartaric acidic and Citric acid. They are formulated in such a way that when in 
contact with the acidity gastric contents, CO2 is liberated and gets entrapped in 
swollen hydrocolloids, which provides buoyancy to the dosage form.  [Shweta Arora, 
et.al. 2005] 
 
                                                                                                                                                                        
                  A) Penetration of water 
            B) Generation of CO2 & floating 
C) Dissolution of drug 
 
Figure 1: Stages of floating mechanism 
 
NON-EFFERVESCENT FLOATING DOSAGE FORM 
Non-effervescent floating dosage form use a gel forming or swellable 
cellulose type of hydrocolloids, polysaccharides and matrix forming polymers like 
polycarbonate, polyacrylate, polymethacrylate, and polystyrene. The formulation 
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method includes a simple approach of thoroughly mixing the drug and the gel 
forming hydrocolloid. After oral administration this dosage form swells in contact 
with gastric fluids and attains a bulk density of <1. The air entrapped within the 
swollen matrix imparts buoyancy to the dosage form. [Shweta Arora, et.al. 2005] 
Sheth and Tossounian [Sheth PR and Tossounian JL, 1978] developed an 
Hydrodynamically Balanced System containing a homogeneous mixture of drug and 
the hydrocolloid in a capsule, which upon contact with gastric fluid acquired and 
maintained a bulk density of less than 1 thereby being buoyant on the gastric contents 
of stomach until all the drug was released (Figure 2). 
 
Figure 2: Working principle of the hydrodynamically balanced system 
Sheth and Tossounian [Sheth PR and Tossounian JL, 1979] developed 
hydrodynamically balanced sustained release tablets containing drug and hydrophilic 
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hydrocolloids, which on contact with gastric fluids at body temperature formed a soft 
gelatinous mass on the surface of the tablet and provided a water-impermeable colloid 
gel barrier on the surface of the tablets. The drug slowly released from the surface of 
the gelatinous mass that remained buoyant on gastric fluids. (Figure 3 A and B) 
 
Figure 3: (A) Intra gastric floating tablet 
 
 
 
 
 
 
 
 
 
Figure 3: (B) Intra gastric floating bilayer tablet 
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FLOATING DRUG DELIVERY SYSTEM MECHANISM 
As per mechanism of expansion of expandable dosage form, the generation of 
gas on contact with gastric juice is preferred. While various gases will be suitable from 
the physiological point of view, among of them, nitrogen, nitrous oxide, methane and 
other gases, expansion with CO2 is particularly preferred since this can be released 
readily and in a relatively large amount. In principle suitable substance from which 
CO2 can be released are various carbonates and hydrogen carbonates. On account of 
good tolerability and high yield, Hydrogen Carbonate (NaHCO3) or Sodium Hydrogen 
Carbonate is preferred. [Asmussen B, et.al. 2001]  
 
APPROACHES TO DESIGN FLOATING DOSAGE FORMS 
The following approaches have been used for the design the floating dosage 
form of single unit system.  
  
 
 
 
 
 
 
Figure 4: Intra gastric residence positions of floating and non-floating units 
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Single-Unit Dosage Forms  
In Low-density approach   [Deshpande AA, et.al. 1997] the globular shells 
apparently having lower density than that of gastric fluid can be used as a carrier for 
drug for its controlled release. A buoyant dosage form can also be obtained by using a 
fluid-filled system that floats in the stomach. In coated shells24 popcorn, poprice, and 
polystyrol have been exploited as drug carriers. Sugar polymeric materials such as 
methacrylic polymer and cellulose acetate phthalate have been used to undercoat 
these shells. These are further coated with a drug-polymer mixture. The polymer of 
choice can be either ethylcellulose or hydroxypropyl cellulose depending on the type 
of release desired. Finally, the product floats on the gastric fluid while releasing the 
drug gradually over a prolonged duration.  
Fluid- filled floating chamber [Joseph NJ, et.al. 2002] type of dosage forms 
includes incorporation of a gas-filled floatation chamber into a microporous 
component that houses a drug reservoir. Apertures or openings are present along the 
top and bottom walls through which the gastrointestinal tract fluid enters to dissolve 
the drug. The other two walls in contact with the fluid are sealed so that the 
undissolved drug remains therein. The fluid present could be air, under partial 
vacuum or any other suitable gas, liquid, or solid having an appropriate specific 
gravity and an inert behavior. The device is of swallowable size, remains afloat 
within the stomach for a prolonged time, and after the complete release the shell 
disintegrates, passes off to the intestine, and is eliminated. Hydrodynamically 
balanced systems (HBS) are designed to prolong the stay of the dosage form in the 
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gastro intestinal tract and aid in enhancing the absorption. Such systems are best 
suited for drugs having a better solubility in acidic environment and also for the drugs 
having specific site of absorption in the upper part of the small intestine. To remain in 
the stomach for a prolonged period of time the dosage form must have a bulk density 
of less than 1. It should stay in the stomach, maintain its structural integrity, and 
release drug constantly from the dosage form. The success of HBS capsule as a better 
system is best exemplified with chlordiazeopoxide hydrochloride. The drug is a 
classical example of a solubility problem wherein it exhibits a 4000-fold difference in 
solubility going from pH 3 to 6 (the solubility of chlordiazepoxide   hydrochloride is 
150 mg/ml and is ~0.1 mg/ml at neutral pH).  
HBS of chlordiazeopoxide hydrochloride had comparable blood level time 
profile as of three 10-mg commercial capsules. HBS can either be formulated as a 
floating tablet or capsule. Many polymers and polymer combinations with wet 
granulation as a manufacturing technique have been explored to yield floatable 
tablets.  
Various types of tablets (bilayered and matrix) have been shown to have 
floatable characteristics. Some of the polymers used are hydroxypropyl cellulose, 
hydroxypropylmethylcellulose, crosspovidone, sodium carboxymethyl cellulose, and 
ethyl cellulose. Self-correcting floatable asymmetric configuration drug delivery 
system employs a disproportionate 3-layer matrix technology to control drug release.  
The 3-layer principle has been improved by development of an asymmetric 
configuration drug delivery system in order to modulate the release extent and 
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achieve zero-order release kinetics by initially maintaining a constant area at the 
diffusing front with subsequent dissolution/erosion toward the completion of the 
release process. The system was designed in such a manner that it floated to prolong 
gastric residence time in vivo, resulting in longer total transit time within the 
gastrointestinal tract  environment with maximum absorptive capacity and 
consequently greater bioavailability. This particular characteristic would be 
applicable to drugs that have pH-dependent solubility, a narrow window of 
absorption, and are absorbed by active transport from either the proximal or distal 
portion of the small intestine.  
APPLICATION OF FLOATING DRUG DELIVERY SYSTEM 
1) Sustained Drug Delivery 
HBS can remain in the stomach for longer period and hence can release the 
drug over a prolonged period of time. The problem of short gastric residence time 
encountered with a CR formulation hence can be overcome with these systems. These 
systems have a bulk density of <1 as a result of which they can float on the gastric 
contents. These systems are relatively large in size and passing from the pyloric 
opening is prohibited. Similarly a comparative study [Erni W and Held K, 1987] 
between the Madopar HBS and Madopar standard formulation was done and it was 
shown that the drug was released up to 8 hours. In vitro in the former case and the 
release was essentially complete in less than 30 minutes in the latter case. 
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2) Site specific Drug Delivery 
These systems are particularly advantageous for drugs that are specifically 
absorbed from the stomach or the proximal part of the small intestine e.g. Riboflavin 
and Furosemide. Furosemide is primarily absorbed from the stomach followed by the 
duodenum. It has been reported that in monolithic floating dosage form with 
prolonged gastric residence time was developed and the bioavailability was increased. 
AUC obtained with the floating tablets was approximately 1.8 times those 
conventional Furosemide tablets. [Menon A, et.al. 1994] 
3) Absorption enhancement 
Drugs that have poor bioavailability because of site-specific absorption from 
the upper part of gastrointestinal tract are potential candidates to be formulated as 
floating drug delivery systems, thereby maximizing their absorption.  Miyazaki S, 
et.al. [Miyazaki S, et.al. 1988] conducted pharmacokinetic studies on floating 
granules of Indomethacin prepared with chitosan and compared the peak plasma 
concentration and AUC with the conventional commercially available capsules. It 
was concluded that the floating granules prepared with chitosan were superior in 
terms of decrease in peak plasma concentration and maintenance of drug in plasma. 
Ichikawa M, et.al. [Ichikawa M, et.al. 1991] developed a multiparticulate system that 
consisted of floating pills of a drug (P– amino benzoic acid) having a limited 
absorption site in the gastrointestinal tract. It was forced to have 1.61 times greater 
AUC than the control pills. 
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LIMITATION OF FLOATING DRUG DELIVERY SYSTEM 
Floating Drug Delivery System (FDDS) is associated with certain limitations. 
Drugs that irritate the mucous, those that have multiple absorption sites in the 
gastrointestinal tract, and those that are not stable at gastric pH are not suitable 
candidates to be formulated as floating dosage forms.  
Flotation as a retention mechanism requires the presence of liquid on which the 
dosage form can float on the gastric contents [Chitnis V, et.al. 1991], or the dosage 
form can be administered with a full glass of water to provide the initial fluid for 
buoyancy. Also single unit floating capsules or tablets are associated with an “all or 
none concept”, but this can be overcome by formulating multiple units system like 
floating microspheres (or) micro balloons. [Rouge N, et.al. 1997]  
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BACKGROUND OF THE INVESTIGATION 
Diabetes Mellitus is a group of metabolic disease characterized by 
hyperglycemia resulting from defects in insulin secretion, insulin action or both. 
[Diabetes care 2004]  Chronic hyperglycemia of diabetes is associated with long term 
damage, dysfunction, and failure of various organs especially the eyes, kidney, 
nerves, heart, and blood vessels. 
Classification of Diabetes Mellitus 
Type 1 :  Diabetes Mellitus: (β-cell destruction usually leading to absolute  
     insulin deficiency) 
Type  2  :  Diabetes Mellitus. 
Importance of oral medication in diabetes   
Oral medication for the management of Type 2 diabetes has been available in 
the US since 1957, when the sulfonyl urea drug Tolbutamide was approved by the 
FDA. This was followed in the year 1950’s and 1960’s by the approval of other first 
generation sulfonyl urea – Chlorpropamide, Acetohexamide, and Tolazolamide. 
Second generation sulfonyl urea – Glipizide and Glyburide were introduced in 
the year 1984. More than a decade later in 1995, the biguanide, Metformin was 
approved by the FDA, followed in 1996 by Glimepiride a sulfonyl urea, drug – 
Agarbose α-glucosidase inhibitor. 
In 1997 – Trogilitazone the first Thiazolidinedione – insulin sensitizer was 
approved, but it was withdrawn in 2000 due to liver toxicity. Thiazolidinedione 
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insulin sensitizer, Rosiglitazone, and Pioglitzone, the second glucosidase inhibitor 
Migilitol were marketed beginning in 1999.  
Table 1: Dispensed outpatient prescription for oral antidiabetic 
medication in US [Diane K.W, et.al. 2003] 
Generic Name Trade Name Year of approved 
Sulfonyl Ureas   
Tolbutamide Orinase 1957 
Chlorpropamide Diabinese, Glucamide 1958 
Acetohexamide Dymelor 1964 
Tolazomide Tolinase 1966 
Glipizide Glucotrol, Glucotrol XL 1987 
Glyburide 
Diabeta, Micronase, 
Glynase 
1984 
GLIMEPIRIDE Amaryl 1996 
Biguanide   
Metformin Glucophage 1995 
Glycosidase inhibitors   
Agarbose Precose 1995 
Migilitol Glyset 1999 
Thiazolidinedione 
insulin sensitizer   
Troglitazone Rezulin 1997 
Rosiglitazone Avandia 1999 
Pioglitazone Actos 1999 
Non Sulfonyl Urea 
Insulin Secretagogues   
Repaglinide Prandin 1998 
Nateglinide Starlix 2001 
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In 1999 23.4 million, outpatient prescription for oral antidiabetic medication 
were dispensed in US. By 2001 this number had increased 3.9 fold to 94.84 million 
prescriptions.  
Through 1996, the market was dominated by use of second generation 
sulphonyl urea medication, Glyburide, Glipizide, and Glimepiride. These medications 
together accounted for 77% of prescription in 1990 and 75% of prescription in 1996. 
No sustained release dosage form for Glimepiride is available till date. 
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OBJECTIVES 
 
Gastro Retentive Drug Delivery Systems are particularly advantageous for 
drugs that are specifically absorbed from the stomach or the proximal part of the 
small intestine. It has been reported that in monolithic floating dosage form with 
prolonged gastric residence time was developed and the bioavailability was increased. 
Hydrodynamically Balanced System (HBS) can remain in the stomach for longer 
periods and hence can release the drug over a prolonged period of time encountered 
with a Controlled Release formulation hence can be overcome with these systems. 
[Shweta Arora, et.al. 2005] 
The bioavailability of certain antidiabetic drugs reduces due to the 
pathophysiology of the patient. In such cases prolonged gastric retention of the 
therapeutic moiety may offer numerous advantages, including improved 
bioavailability, therapeutic efficiency and possible reduction of dose. 
Glimepiride is second generation new sulfonyl urea oral antidiabetic. 
Glimepiride is poorly soluble in acidic environment. When it is given orally in 
healthy people, it absorbs rapidly and completely. However, its absorption is erratic 
in diabetic patients due to impaired gastric motility or gastric emptying. This erratic 
absorption of Glimepiride becomes clinically significant, since the efficacy of short 
acting sulfonylurea is dependent upon the absorption rate of the drug. Hence, to 
overcome the above mentioned drawbacks the present study aims to develop 
Glimepiride as Floating Drug Delivery System (FDDS) and its evaluation.  
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PLAN OF WORK 
Pre-formulation studies 
Formulation development of Glimepride as Floating Drug Delivery 
Evaluation of Gastro Retentive Formulations 
Evaluation of 
Granules 
Angle of repose 
Bulk Density / 
Tapped Density 
Compressibility 
Buoyancy Test 
Floatability 
Dissolution Kinetics 
Friability 
Weight variation 
Evaluation of 
Compressed Tablets
Diameter 
Thickness 
Hardness 
Content uniformity 
Assay 
Dissolution 
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LITERATURE REVIEW 
 
Abubakr O. Nur and Jun S. Zhang (2000), [Abubakr O. Nur, et.al. 2000] 
Two viscosity grades of Hydroxypropylmethylcellulose (HPMC 4000 and 15000 cps) 
and Carbopol 934P were used to prepare Captopril floating tablets. In vitro 
dissolution was carried out in simulated gastric fluid (enzyme free) at 37 ± 0.1ºC 
using the USP apparatus 2 basket method. Compared to conventional tablets release 
of Captopril from these floating tablets was apparently prolonged; as a result, a 24-hr 
controlled-release dosage form for Captopril was achieved. Drug release best fit both 
the Higuchi model and the Korsmeyer and Peppas equation, followed by first order 
kinetics. While tablet hardness and stirring rate had no or little effect on the release 
kinetics, tablets hardness was found to be a determining factor with regard to the 
buoyancy of the tablets. 
Anand Kumar, Sri Vastava, Devendra Narayanrao Ridhurkar, Saurabh 
Wadhwa (2005), [Anand Kumar, et.al. 2005], Involves preparation and evaluation of 
floating microspheres with Cimetidine as model drug for prolongation of gastric 
residence time. In vitro studies demonstrated diffusion controlled drug release from 
the microspheres.  
Arati A. Dehpande, Navnit H. Shah: Christopher T. Rhodes, and 
Waseem Malick (1997), [Arati A. Dehpande, et.al. 1997], report on the development 
of a novel controlled- release gastric retention system, which consists of a matrix 
tablet, coated with a permeable membrane. When immersed in simulated gastric fluid, 
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the tablet expands. The tablet remains expanded for eighteen to twenty hours, during 
which time the drug is released. The tablet then either disintegrates into fragments or 
loses its integrity. 
Asha Patel, Subhabrata Ray, Ram Sharnagat Thakur (2006), [Asha Patel, 
et.al. 2006], the floating microshperes have been utilized to obtain prolonged and 
uniform release in the stomach for development of a once daily formulation. The 
major advantage of the preparation technique includes short processing time, the lack 
of exposure of the ingredients to high temperature and high encapsulation 
efficiencies. In the present study, preparation of Metformin hydrochloride floating 
microspheres, evaluation of Drug Dosage System in vitro, prediction of the release 
and optimization of floatation of drug release pattern to match target release profile 
was investigated. The developed floating microspheres of Metformin hydrochloride 
may be used in clinic for prolonged drug release in stomach for at least 8 hours. There 
by improving the bioavailability and patient compliance.  
Baumgartner S, et.al. [Baumgartner S, et.al. 2000], developed a matrix-
floating tablet incorporating a high dose of freely soluble drug. The formulation 
containing 54.7% of drug, HPMC K4M, Avicel PH 101, and a gas-generating agent 
gave the best results. It took 30 seconds to become buoyant. In vivo experiments with 
fasted state beagle dogs revealed prolonged gastric residence time. The comparison of 
gastric motility and stomach emptying between humans and dogs showed no big 
difference and therefore it was speculated that the experimentally proven increased 
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gastric residence time in beagle dogs would be compared with known literature for 
humans, where this time is less than 2 hours.  
Brijesh S. Dave, Avani F, Amin and Madhabhai M. Patel (2004), [Brijesh 
S. Dave, et.al. 2004], this research was to prepare a Gastric Retentive Drug Delivery 
System of Ranitidine hydrochloride. These studies indicate that the proper balance 
between a release rate enhances and a release rate retardant can produce a drug 
dissolution profile similar to a theoretical dissolution profile. 
Shweta Arora, Javel Ali, Alka Ahuja, Roop K. Khar, and Sanjula 
Baboota (2005), [Shweta Arora, et.al. 2005] Floating Drug Delivery System (FDDS) 
was to compile the recent mechanism of floatation to achieve gastric retention. This 
review also summarizes the in vitro techniques, in vivo studies to evaluate the 
performance and application of floating systems. These systems are useful to several 
problems encountered during the development of a pharmaceutical dosage form. 
Hiroshi Yuasa, Yuki Takashima and Yoshio Kanaya (1996), [Hiroshi 
Yuasa, et.al. 1996], prepared an intragastric floating preparation using porous calcium 
silicate as a floating carrier, which has floating ability due to the air included in the 
pores when they are covered with polymer, it also has a sustained drug release 
property. 
Shoufeng Li, Senshang Lin, Bruce P. Daggy, Haresh L. Mirchandani and 
Yie W.Chien (2002), [Shoufeng Li, et.al. 2002], to evaluate the contributing of 
formulation variables on the floating properties of a Gastric Floating Drug Delivery 
System using a continuous floating monitoring system and statistical experiment 
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design. The effect of formulation variables on the floating property of the delivery 
system, the effect of formulation variables in the floating property of the delivery 
system and their ranges could be identified. Incorporation of hydrophobic agents such 
as Magnesium stearate could significantly improve the floating capacity of the 
Gastric Floating Drug Delivery System.  
Nurten Ozedemir, Sefika Ordu, Yalcin ozkan (2000), [Nurten Ozdemir, 
et.al. 2000], the purpose of enhancement of the bioavailability of Furosemide, a 
floating dosage form with controlled release of Furosemide was designed in the 
study. A floating dosage form with controlled release of Furosemide was designed in 
this study, a considerably significant correlation was detected between in vivo results 
and in vitro data of the dissolution rate, and it was concluded that the modified 
continuous flow through cell method is usable for in vitro dissolution rate test of 
floating dosage forms.  
Libo Yang and Reza Fassihi (1996), [Libo Yang, et.al. 1996], a new 
approach based on the three layer matrix technology to control drug release for oral 
administration is presented. Polyethylene oxide polymers of various molecular 
weights together with Theophylline as drug model and other excipients have been 
directly compressed into a three-layer asymmetric floatable system. The core layer 
contains the active drug while external layers with different thickness, composition, 
and erosion rates are designed to delay the hydration of the middle layer, restrict the 
early drug diffusion only through cylindrical side surfaces of the tablet, and provide 
controlled drug release. Results show that during 16hr dissolution study drug is 
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completely released following the zero-order kinetics with no burst effect. The release 
rate remains around 0.1mg min-1 throughout the dissolution study. The release 
kinetics is independent of changes in pH and compression force but dependent on 
layer thickness and formulation components. It appears that the operating release 
mechanism is based on the existence of a balance between the velocities of advancing 
glassy/rubbery front and erosion at the swollen polymer / dissolution front. 
Hamid A, Merchant, Harris M.Shoaib, Jaweria Tazeen, and Rabia 
I.Yousuf (2006), [Hamid A. et.al. 2006], Hydrophilic polymer matrix systems are 
widely used in oral controlled drug delivery because they make it easier to achieve a 
desirable drug release profile, they are cost effective, and they have broad US Food 
and Drug Administration acceptance. The hydrophilic polymer matrix system consists 
of hydrophilic polymer, drug, and other excipients distributed throughout the matrix. 
This dynamic system is dependent on polymer wetting, hydration, and dissolution for 
controlled release of drug. At the same time, other soluble excipients or drug 
substances will also wet, dissolve, and diffuse out of the matrix, where as insoluble 
excipients or drug substances will be held in place until the surrounding polymer, 
excipients, or drug complex erodes or dissolves away. Hydroxypropylmethylcellulose 
(HPMC), which is commonly used in hydrophilic matrix drug delivery systems, is 
mixed alkyl hydroxyalkylcellulose ether containing methoxyl and hydroxypropyl 
groups. The hydration rate of HPMC depends on the nature of these substituents, such 
as the molecular structure and the degree of substitution. Specifically, the hydration 
rate of HPMC increases with an increase in the hydroxypropyl content. The solubility 
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of HPMC is pH independent. HPMC has been found to be a very versatile material 
for the formulation of soluble matrix tablets. It is a widely accepted pharmaceutical 
excipient and is included in all major compendia. Because HPMC is available in a 
wide range of molecular weights, effective control of gel viscosity is easily provided. 
K. Raghuram Reddy, Srinivas Mutalik, and Srinivas Reddy (2003), [K. 
Raghuram Reddy, et.al. 2003], the objective of the present study was to develop 
once-daily sustained release matrix tablets of Nicorandil, a novel potassium channel 
opener used in cardiovascular diseases. The tablets were prepared by the wet 
granulation method. Ethanolic solutions of ethylcellulose (EC), Eudragit RL-100, 
Eudragit RS-100, and polyvinylpyrrolidine were used as granulating agents along 
with hydrophilic matrix materials like hydroxypropylmethylcellulose (HPMC), 
sodium carboxymethylcellulose, and sodium alginate. The granules were evaluated 
for angle of repose, bulk density, compressibility index, total porosity, and drug 
content. The tablets were subjected to thickness, diameter, weight variation test, drug 
content, hardness, friability, and in vitro release studies. The granules showed 
satisfactory flow properties, compressibility, and drug content. All the tablet 
formulations showed acceptable pharmaco technical properties and complied with in-
house specifications for tested parameters. According to the theoretical release profile 
calculation, a once-daily sustained-release formulation should release 5.92 mg of 
Nicorandil in 1 hour, like conventional tablets, and 3.21 mg per hour up to 24 hours.  
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Esra Demirtürk / Levent Öner (2005), [Esra Demirthiirk, et.al. 2005], three 
categories of dissolution test specifications for immediate release drug products are 
described in the guidance. Single point specifications are recommended as a routine 
quality control test for highly soluble and rapidly dissolving drug products. This 
comparison method can be employed in evaluating scale-up and post-approval 
changes such as manufacturing site changes, component and composition changes, 
equipment changes and process changes. Two-point specifications are suggested for 
characterizing the quality of drug product and for accepting product sameness under 
SUPAC-related changes. In the presence of certain minor changes the single point 
dissolution test may be adequate to ensure unchanged product quality and 
performance. For more major changes a dissolution profile comparison performed 
under identical conditions for the product before and after the changes is 
recommended. Dissolution profiles may be considered similar by virtue of overall 
profile similarity and similarity at every dissolution sample time point. 
Ozdemir et. al. [Ozdemir et.al. 2000] developed floating layers tablet with 
controlled release for Furosemide. Radiographic studies on 6 healthy male volunteers 
revealed that floating tablets were retained in stomach for 6 hours and further blood 
analysis studies showed that bioavailability of these tablets was 1.8 times more than 
that of the conventional tablets. On measuring the volume of urine the peak diuretic 
effect seen in the conventional tablets was decreased and prolonged in the case of 
floating dosage form. 
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Choi BY, et. al. [Choi BY, et.al. 2002], prepared floating alginate beads using 
gas-forming agents (Calcium carbonate and Sodium bicarbonate) and studied the 
effect of CO2 generation on the physical properties, morphology, and release rates. 
The study revealed that the kind and amount of gas forming agent had a profound 
effect on the size, floating ability, pore structure, morphology, release rate, and 
mechanical strength of the floating beads. It was concluded that calcium carbonate 
formed smaller but stronger beads than sodium bicarbonate. Calcium carbonate was 
shown to be a less effective gas-forming agent than Sodium bicarbonate but it 
produced superior floating beads with enhanced control of drug release rates. In-vitro 
floating studies revealed that the beads free of gas forming agents sank uniformly in 
the media while the beads containing gas forming agents in proportions ranging from 
5:1 to 1:1 demonstrated excellent floating (100%).  
Talwar N, et.al. [Talwar N, et.al. 2001], developed a once daily formulation 
for oral administration of Ciprofloxacin. The formulation was composed of 69.9% 
Ciprofloxacin base, 0.34% sodium alginate, 1.03% xanthum gum, 13.7% sodium 
bicarbonate and 12.1% cross linked poly vinyl pyrrolidine. The viscolysing agent 
initially and the gel forming polymer later formed a hydrated gel matrix that 
entrapped the gas, causing the tablet to float and be retained in the stomach or upper 
part of the small intestine. The hydrated gel matrix created a tortuous diffusion path 
for the drug, resulting in sustained release of the drug. 
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Moursy NM, et.al. [Moursy NM, et.al. 2003], developed sustained release 
floating capsules of Nicardipine hydrochloride. For floating hydrocolloids of high 
viscosity grades were used and to aid in buoyancy. Sodium bicarbonate was added to 
allow evolution of CO2. In vitro analysis of a commercially available 20mg capsule of 
Nicardipine hydrochloride (MICARD) was performed for comparison. Results 
showed an increase in floating with increase in proportion of hydrocolloid. Inclusion 
of sodium bicarbonate increased buoyancy. 
Nur AO, and Zhang JS [Nur AO and Zhang JS, 2000], developed floating 
tablets of Captopril using HPMC (4000 and 15000cps) and Carbopol 934P. In vitro 
buoyancy studies revealed that tablets of 2 Kg/cm2 hardness after immersion into the 
floating media floated immediately and tablets with hardness 4 Kg/cm2 sank for 3 to 4 
minutes and then came to the surface tablets in both cases remained floating for 
24hrs. 
Hiroshi Yuasa, Yuki Takashima, and Yoshio Kanaya (1996), [Hiroshi 
Yuasa, et.al. 1996], prepared an intragastric floating preparation using porous calcium 
silicate (Florite RE, FLR) as a floating carrier, which has floating ability due to the air 
included in the pores when they are covered with a polymer, it also has a sustained 
drug release property. Floating granules were prepared by dropping a 5 or 10% (w/v 
of ethanol solution of hydroxypropylcellulose (HPC) and ethylcellulose (EC) in 4 
different concentration ratios while the Calcium silicate was being agitated in a 
beaker. After the mixture was dried in vacuo and sieved, we regarded the granules 
obtained as primary coated granules (PCG). After drying, the ethanol solution of the 
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polymer was dropped and dried in vacuo again, and sieving was carried out to obtain 
secondary coated granules (SCG). The floating property and surface and inner 
structures of PCG and SCG were studied. Further, we prepared PCG and SCG 
including Diclofenac sodium (DS) (DS-PCG, DS-SCG) as a model drug, and the 
release profile from these granules was observed. The floating property of SCG was 
better than that of PCG. A longer floating time was observed with a higher polymer 
concentration and a lower HPC composition ratio. It was observed by a scanning 
electron microscope  (SEM) and the pore size distribution that more pores of Calcium 
silicate in SCG were covered with polymer that those in PCG. DS-SCG showed a 
smaller release rate than DS-PCG. These suggest that Calcium silicate is a useful 
floating carrier for the development of floating and sustained release preparations.  
Shozo Miyazaki, Hideki Yamaguchi, Chizuko Youkouchi, Masahiko 
Takada, and Wei-Min Hou (1998), [Shozo Miyazaki, et.al. 1998], the release rate of 
Indomethacin from chitosan granules was compared with that of conventional 
commercial Indomethacin capsules and a sustained-release capsule. In contrast with 
the rapid release of commercial conventional capsule form, sustained release from the 
chitosan granules was observed. Furthermore, the release rate could be controlled by 
changing the mixing ratio of drug and chitosan. The potential of chitosan granules as 
an oral sustained-release dosage form of Indomethacin was investigated in rabbits. 
When a conventional commercial capsule was administered orally to rabbits, the 
plasma concentration reached the maximum level 1h after administration. In the case 
of the granules with a 1:2 mixture of drug and chitosan, the chitosan granules did not 
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give a sharp peak of plasma concentration, but produced a sustained plateau level of 
Indomethacin. Area under the plasma concentration curve (AUC) (0-8h) value of 
chitosan granules showed a slightly higher value than that of commercial capsules. 
This may be due to slow rate of release from the chitosan granules and the longer 
residence time in the stomach. 
Stanley S. Davis, Anita F. Stockwell, Margaret J. Taylor, John G. Hardy, 
David R. Whalley, C.G. Wilson, Helle Bechgaard, and Finn N. Christensen 
(1986), [Stanley S. Davis, et.al. 1986], the gastric emptying of pellets and single units 
of different densities has been followed in healthy subjects using the technique of 
gamma scintigraphy. The gastric emptying of the light pellets was affected by their 
buoyancy in the upper part of the stomach. However, the mean gastric emptying rates 
of pellets and single units were not significantly affected by density. Floating or 
buoyant delivery systems may have little advantage over conventional systems. The 
presence of food in the stomach was found to be the major factor in determining the 
gastric emptying of single units. 
Joseph A. Fix, Robyn Cargill, and Karen Engle (1993), [Joseph A. Fix, 
et.al. 1993], the performance of controlled-release dosage forms can depend on the 
location of the dosage form within the gastrointestinal (GI) tract. The ability to retain 
a dosage form in a specific location of the GI tract, preferably the stomach, would 
provide constant exposure of the entire absorptive surface of the intestine to the drug 
being released, thereby optimizing conditions for maximal control of drug absorption. 
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Subhash Desai and Sanford Bolton (1993), [Subhash Desai, et.al. 1993], A 
novel floating controlled-release drug delivery system was formulated in an effort 
increase the gastric retention time of the dosage form and to control drug release. The 
buoyancy was attributed to air and oil entrapped in the agar gel network. A floating 
controlled release 300mg Theophylline tablet having a density of 0.67 was prepared 
and compared in vitro and in vivo to Theodur. The in vitro release rate of the floating 
tablet was slower. In vivo scintigraphic studies for a floating and a heavy nonfloating 
tablet, under fasting and non-fasting conditions, showed that the presence of food 
significantly increased the gastric retention time for both tablets, and tablet density 
did not appear to make a difference in the gastric retention time. However, the 
positions of the floating and non-floating tablets in the stomach were very different. 
Bioavailability studies in human volunteers under both fasting and non-fasting 
conditions showed results comparable to those with Theodur. The floating controlled-
release Theophylline tablet maintained constant Theophylline levels of about 
2mg/mL for 24 hr, which may be attributable to the release from the agar gel matrix 
and the buoyancy of the tablet in the stomach. 
Marianne Oth, Michel Franz, Jacques Timmermans, and Andre Moes, 
(1992), [Marianne Oth, et.al. 1992], a bilayer floating dosage unit is proposed to 
achieve local delivery of Misoprostol, a prostaglandin E1 analogue, at the gastric 
mucosa level. The system is a capsule consisting of a floating layer maintaining the 
dosage unit buoyant upon the gastric content and a drug layer formulated to act as a 
sustained-delivery system. The differential design of the two layers allows the 
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optimization of both floating capability and drug release profile. The layers are both 
composed of a hydrophilic matrix based upon hydroxypropylmethyly cellulose 
(HPMC). Parameters influencing the release profiles are described. The use of a large 
capsule increases the gastric residence time (GRT), as it impedes passage through the 
pylorus opening. ϒ-scintigraphic studies were performed to visualize cohesion of the 
two layers in vivo and to determine GRT as a function of meal regimen. The average 
GRTs were 199 ± 69 min after a single meal (breakfast) and 618 ± 208 min after a 
succession of meals. 
Manoj N. Gambhire, Kshitij W. Ambade, Sushma D. Kurmi, Vilasrao J. 
Kadam, and Kisan R. Jadhav (2007), [Manoj N. Gambhire, et.al. 2007], the 
purpose of this research was to prepare a floating drug delivery system of Diltiazem 
hydrochloride (DTZ). Floating matrix tablets of DTZ were developed to prolong 
gastric residence time and increase its bioavailability. Rapid gastro- intestinal transit 
could result incomplete drug release from the drug delivery system above the 
absorption zone leading to diminished efficacy of the administered dose. The tablets 
were prepared by direct compression technique, using polymers such as 
hydroxypropylmethylcellulose (HPMC, Methocel K100M CR), Compritol 888 ATO, 
alone or in combination and other standard excipients. Sodium bicarbonate was 
incorporated as a gas-generating agent. The effects of sodium bicarbonate and 
succinic acid on drug release profile and floating properties were investigated. A 32 
factorial design was applied to systematically optimize the drug release profile. The 
amounts of Methocel K100M CR (X1) and Compritol 888 ATO (X2) were selected 
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as independent variables. The time required for 50% (t50) and 85% (t85) drug 
dissolution were selected as dependent variables. The results of factorial design 
indicated that a high level of both Methocel K100M CR (X1) and Compritol 888 
ATO (X2) favors the preparation of floating controlled release of DTZ tablets. 
Comparable release profiles between the commercial product and the designed 
system were obtained. The linear regression analysis and model fitting showed that 
all these formulations followed Korsmeyer and Peppas model, which had a higher 
value of correlation coefficient (r2). While tablet hardness had little or no effect on the 
release kinetics and was found to be a determining factor with regards to the 
buoyancy of the tablets. 
Dasharath M. Patel, Natvarlal M. Patel,  Nitesh N. Pandya,  and Pranav 
D. Jogani (2007), [Dasharath M. Patel, et.al. 2007], The high cost involved in the 
development of a new drug molecule has diverted the pharmaceutical companies to 
investigate various strategies in the development of new drug delivery systems. Drug 
release from the delivery devices can be sustained up to 24 hours for many drugs 
using current release technologies. However, the real issue in the development of oral 
controlled release dosage forms is to prolong the residence time of the dosage form in 
the stomach or upper gastrointestinal (GI) tract until the drug is completely released. 
Rapid GI transit could result incomplete drug release from the drug delivery device in 
the absorption zone leading to diminished efficacy of the administered dose. Several 
approaches are currently used to retain the dosage form in the stomach. These include 
bioadhesive systems, swelling and expanding systems, floating systems, and other 
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delayed gastric emptying devices. The principle of buoyant preparation offers a 
simple and practical approach to achieve increased gastric residence time for the 
dosage form and sustained drug release. Carbamazepine (CBZ) is used for 
anticonvulsant and anti- neuralgic effects. The popularity of this drug is related to 
several beneficial properties, including proven efficacy in controlling different types 
of seizures.   
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DRUG PROFILE 
GLIMEPIRIDE, a new generation sulphonyl urea [Michihiro Matsuki, et.al. 
2007] has several benefits, rapid and complete absorption after oral administration, a 
lower dose, long duration action, and possible insulin sensitizing effect. Glimepiride 
is an oral blood glucose lowering drug of sulfonyl urea class. 
 
Chemical Name 
Glimepiride (1–[[p-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline-1-carboxamido)ethyl] 
phenyl]  sulfonyl]-3-(trans-4-methylcyclohexyl) urea. 
The CAS registry number is 93479-97-1. 
Molecular formula : C24H34N4O5S 
Molecular weight : 490.62 
Structural formula: 
 
Figure 5: Structure of Glimepiride 
Physical properties : Glimepiride is a white to yellowish white crystalline odorless 
powder. 
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Solubility: Glimepiride is insoluble in water, acid, base, borate and phosphate buffers 
but partially soluble in methanol, ethanol, acetone, and completely soluble in DMF 
[www.aventis.us.com]. 
Chemical properties: Methanolic solution of Glimepiride gives UV absorption at 
229nm. [USP 31, 2008] Aqueous solution of Glimepiride gives maximum absorption 
between 229 and 236nm. [Anju Goyal, and I.Singhvi.2007]  
Log P value : 2.5 
C Log P value : 3.96 [www.tsrlinc.com]  
BCS: Class 2 drug (low solubility high permeability)  
Available strength: 1mg, 2mg, and 4mg 
Mechanism of Action 
The primary mechanism of Glimepiride in lowering blood glucose appears to 
be dependent on stimulating the release of insulin from functioning pancreatic beta 
cells. 
In addition extra pancreatic effect may also play a role in the activity of 
sulfonyl urea such as Glimepiride. This is supported by both clinical and pre-clinical 
studies demonstrating the Glimepiride administration can lead to increased sensitivity 
of peripheral tissues to insulin. 
 
Pharmacokinetics 
Absorption: After oral administration, Glimepiride is completely (100%) absorbed 
from the GI tract. Studies with single oral dose in normal subjects and with multiple 
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oral doses in patients with Type-2 diabetes has shown significant absorption of 
Glimepiride with  1 hour after administration and peak drug levels at 2 to 3hours. 
Distribution: After intravenous (IV) dosing in normal subjects, the volume of 
distribution (Vd) was 8.8L (113ml/kg), and the total body clearance (Cl) was 47.8 
ml/min. Protein binding was greater than 99.5%. 
Metabolism: Glimepiride is completely metabolized by oxidative biotransformation 
after either an IV or oral dose. The major metabolites are the cyclohexyl hydroxyl 
methyl derivative (M1) and the carboxyl derivative (M2). Cytochrome P450 2C9 has 
been shown to be involved in the biotransformation of Glimepiride to M1. M1 is 
further metabolized to M2 by one or several cytosolic enzymes. M1, but not M2, 
possesses about 1/3 of the pharmacological activity as compared to its parent in an 
animal model. 
Excretion: When 14C-Glimepiride was given orally, approximately 60% of the total 
radioactivity was recovered in the urine in 7 days and M1 (predominant) and M2 
accounted for 80 – 90% of that recovered in the urine. Approximately 40% of that 
recovered in feces. No parent drug was recovered from urine or feces.  
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Pharmacokinetic Parameters 
Table 2: Pharmacokinetic Parameters 
Parameter Single Dose 
Cmax (ng/ml)  
1 mg 103± 34 (12) 
2 mg 177 ± 44 (12) 
4 mg 308 ± 69 (12) 
8 mg 551 ± 152 (12) 
Tmax (h) 1.4 ± 0.8 (48) 
Cl/f(ml/min) 52.1 ± 16.0 (48) 
Vd/f(l) 21.8 ± 13.9 (48) 
T1/2(h) 5.3 ± 4.1 (48) 
 
CL/f=Total body clearance after oral dosing 
Vd/f=Volume of distribution calculated after oral dosing 
 
Adverse reactions 
GASTRO INTESTINAL REACTIONS 
Vomiting, gastro intestinal pain and diarrhoea have been reported. 
DERMATOLOGIC REACTIONS 
Allergic skin reactions, e.g. Pruritus, Erythema, Urticaria occurs. 
HEAMATOLOGIC REACTIONS 
Leukopenia, Agranulocytosis, Thrombocytopenia, Hemolytic Anemia, Aplastic 
Anemia, and Pancytopenia have been reported. 
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Indications and Usage   
Glimepiride is indicated as an adjunct to diet and exercise to lower the blood 
glucose in patient with Type 2 diabetes mellitus. Hypoglycemia cannot be controlled 
by diet and exercise alone. Glimepiride may be used concomitantly with Metformin 
when diet, exercise, Glimepiride or Metformin alone does not adequate glycemic 
control.  
 
Dosage and Administration [Package insert of Amaryl tablets 1, 2 and 4 mg] 
Usual starting dose of Glimepiride initial therapy is 1mg to 2mg once daily, 
administered with breakfast or first main meal. 
Patient who may be more sensitive to Hypoglycemic drugs should be started 
at 1mg once daily, and should be titrated carefully. 
The maximum starting dose of Glimepiride should not be more than 2mg. The 
usual maintenance dose is 1 to 4mg once daily. The maximum recommended dose is 
8mg once daily. 
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POLYMER PROFILE 
Polymer Profile 
The gastro retentive formulation contains the following excipients to provide 
the buoyancy for the formulation. 
1. Gas forming agent 
2. Gel forming polymer 
3. Rate controlling polymer 
4. Diluent 
5. Lubricant 
 
Gas forming agent: Sodium bicarbonate [Raymond C. Rowe, et.al. 2006] 
Nonproprietary Names 
• BP: Sodium bicarbonate 
• JP: Sodium bicarbonate 
• PhEur: Natrii hydrogenocarbonas 
• USP: Sodium bicarbonate 
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Synonyms 
Baking soda; E500; Effer-Soda; monosodium carbonate; Sal de Vichy; sodium acid 
carbonate; sodium hydrogen carbonate. 
Chemical Name and CAS Registry Number 
Carbonic acid monosodium salt [144-55-8] 
Empirical Formula and Molecular Weight 
NaHCO3, 84.01 
Structural Formula 
NaHCO3 
Functional Category 
Alkalizing agent; therapeutic agent. 
Applications in Pharmaceutical Formulation 
Sodium bicarbonate is generally used in pharmaceutical formulations as a 
source of carbon dioxide in effervescent tablets and granules. It is also widely used to 
produce or maintain an alkaline pH in a preparation. 
In effervescent tablets and granules, sodium bicarbonate is usually formulated 
with citric and/or tartaric acid; combinations of citric and tartaric acid are often 
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preferred in formulations as citric acid alone produces a sticky mixture that is difficult 
to granulate, while if tartaric acid is used alone, granules lose firmness. When the 
tablets or granules come into contact with water, a chemical reaction occurs, carbon 
dioxide is evolved. 
Recently, sodium bicarbonate has been used as a gas-forming agent in alginate 
raft systems and in floating, controlled-release oral dosage forms of furosemide and 
cisapride. Tablet formulations containing sodium bicarbonate have been shown to 
increase the absorption of paracetamol, and improve the stability of levothyroxine.  
Therapeutically, sodium bicarbonate may be used as an antacid, and as a 
source of the bicarbonate anion in the treatment of metabolic acidosis. Sodium 
bicarbonate may also be used as a component of oral rehydration salts and as a source 
of bicarbonate in dialysis fluids. 
Table 3: Uses of Sodium Bicarbonate 
Use Concentration (%) 
Buffer in tablets 10–40 
Effervescent tablets 25–50 
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Incompatibilities 
Sodium bicarbonate reacts with acids, acidic salts, and many alkaloidal salts, 
with the evolution of carbon dioxide. Sodium bicarbonate can also intensify the 
darkening of salicylates. 
In powder mixtures, atmospheric moisture or water of crystallization from 
another ingredient is sufficient for sodium bicarbonate to react with compounds such 
as boric acid or alum. In liquid mixtures containing bismuth subnitrate, sodium 
bicarbonate reacts with the acid formed by hydrolysis of the bismuth salt. 
In solution, sodium bicarbonate has been reported to be incompatible with 
many drug substances such as ciprofloxacin, amiodarone, nicardipine, and 
levofloxacin.  
Gel forming agent: Carbomer 
Nonproprietary Names 
• BP: Carbomers 
• PhEur: Carbomera 
• USPNF: Carbomer 
• Note that the USPNF 23 contains several individual carbomer monographs 
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Synonyms 
Acritamer; acrylic acid polymer; Carbopol; carboxy polymethylene, polyacrylic acid; 
carboxyvinyl polymer; Pemulen; Ultrez. 
Chemical Name and CAS Registry Number 
Carbomer [9003-01-4] 
Note that carbomer 910, 934, 934P, 940, 941, 971P and 974P resins share the 
common CAS registry number 9003-01-4. Carbomer 1342 is a copolymer and has a 
different CAS registry number. 
Molecular Weight 
The molecular weight of Carbomer resins is theoretically estimated at 7 × 105 
to 4 × 109. In an effort to measure the molecular weight between crosslinks, MC, 
researchers have extended the network theory of elasticity to swollen gels and have 
utilized the inverse relationship between the elastic modulus and MC. Estimated MC 
values of 237 600 g/mol for Carbopol 941 and of 104 400 g/mol for Carbopol 940 
have been reported. In general, carbomer resins with lower viscosity and lower 
rigidity will have higher MC values. Conversely, higher-viscosity, more rigid 
carbomer resins will have lower MC values. 
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Structural Formula 
 
Figure 6: Structure of Carbomer 
Functional Category 
Bioadhesive; emulsifying agent; release-modifying agent; suspending agent; 
tablet binder; viscosity-increasing agent. 
 Applications in Pharmaceutical Formulation 
Carbomers are mainly used in liquid or semisolid pharmaceutical formulations 
as suspending or viscosity-increasing agents. 
Carbomer having low residuals only of ethyl acetate, such as carbomer 971P 
or 974P, may be used in oral preparations, in suspensions, tablets, or sustained release 
tablet formulations. In tablet formulations, carbomers are used as dry or wet binders 
and as a rate controlling excipient. 
 Chapter 7                                                                                                                                Polymer Profile  
 44
Carbomer resins have also been investigated in the preparation of sustained-
release matrix beads, as enzyme inhibitors of intestinal proteases in peptide-
containing dosage forms, as a bioadhesive for a cervical patch and for intranasally 
administered microspheres, in magnetic granules for site-specific drug delivery to the 
esophagus and in oral mucoadhesive controlled drug delivery systems.  
Therapeutically, carbomer gel formulations have proved efficacious in 
improving symptoms of moderate-to-severe dry eye syndrome.  
Table 4: Grades of Carbomers 
Grade 
Carbomer 910 
Carbomer 934 
Carbomer 934P 
Carbomer 940 
Carbomer 941 
Carbomer 1342 
 
 Chapter 7                                                                                                                                Polymer Profile  
 45
Table 5: Uses of Carbomers 
Use Concentration (%) 
Emulsifying agent 0.1–0.5 
Gelling agent 0.5–2.0 
Suspending agent 0.5–1.0 
Tablet binder 5.0–10.0 
 
Incompatibilities 
Carbomers are discolored by resorcinol and are incompatible with phenol, 
cationic polymers, strong acids, and high levels of electrolytes. Certain antimicrobial 
adjutants should also be avoided or used at low levels. Trace levels of iron and other 
transition metals can catalytically degrade carbomer dispersions. Intense heat may be 
generated if a carbomer is in contact with a strong basic material such as ammonia, 
potassium or sodium hydroxide, or strongly basic amines. 
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Certain amino-functional actives form water-insoluble complexes with 
carbomer; often this can be prevented by adjusting the solubility parameter of the 
fluid phase using appropriate alcohols and polyols. 
Carbomers also form pH-dependent complexes with certain polymeric 
excipients. Adjustment of solubility parameter can also work in this situation. 
Rate Controlling Polymer: Hypromellose 
Nonproprietary Names 
• BP: Hypromellose 
• JP: Hydroxypropylmethylcellulose 
• PhEur: Hypromellosum 
• USP: Hypromellose 
Synonyms 
Benecel MHPC; E464; hydroxypropyl methylcellulose; HPMC; Methocel; 
methylcellulose propylene glycol ether; methyl hydroxypropylcellulose; Metolose; 
Tylopur. 
Chemical Name and CAS Registry Number 
Cellulose hydroxypropyl methyl ether [9004-65-3] 
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Molecular Weight 
Molecular weight is approximately 10 000–1 500 000. The JP 2001 includes 
three separate monographs for hypromellose: hydroxypropylmethylcellulose 2208, 
2906, and 2910, respectively. 
Structural Formula 
 
Figure 7: Structure of Hypromellose 
where R is H, CH3, or CH3CH(OH)CH2 
Functional Category 
Coating agent; film-former; rate-controlling polymer for sustained release; 
stabilizing agent; suspending agent; tablet binder; viscosity-increasing agent. 
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Applications in Pharmaceutical Formulation   
Hypromellose is widely used in oral, ophthalmic and topical pharmaceutical 
formulations. 
In oral products, hypromellose is primarily used as a tablet binder, in film-
coating, and as a matrix for use in extended-release tablet formulations. 
Concentrations between 2% and 5% w/w may be used as a binder in either wet- or 
dry-granulation processes. High-viscosity grades may be used to retard the release of 
drugs from a matrix at levels of 10–80% w/w in tablets and capsules. 
Hypromellose is also used as an emulsifier, suspending agent, and stabilizing 
agent in topical gels and ointments. As a protective colloid, it can prevent droplets 
and particles from coalescing or agglomerating, thus inhibiting the formation of 
sediments. 
In addition, hypromellose is used in the manufacture of capsules, as an 
adhesive in plastic bandages, and as a wetting agent for hard contact lenses. It is also 
widely used in cosmetics and food products. 
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Table 6: Grades of Hypromellose 
Methocel product Nominal viscosity (mPa s) 
Methocel K100 Premium LVEP 100 
Methocel K4M Premium 4000 
Methocel K15M Premium 15 000 
Methocel K100M Premium 100 000 
 
Incompatibilities 
Hypromellose is incompatible with some oxidizing agents. Since it is 
nonionic, hypromellose will not complex with metallic salts or ionic organics to form 
insoluble precipitates. 
Diluent: Lactose monohydrate 
Nonproprietary Names 
• BP: Lactose monohydrate 
• PhEur: Lactosum monohydricum 
• JP: Lactose 
• USPNF: Lactose monohydrate 
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Synonyms 
Lactochem, Pharmatose, HMS, NF Lactose, CapsuLac, GranuLac, PrismaLac, 
SacheLac, SorboLac, SpheroLac, Tablettose, Inhalac. 
Chemical Name and CAS Registry Number 
O-β-D-Galactopyranosyl-(1→4)-α-D-glucopyranose monohydrate [64044-51-5] 
Empirical Formula and Molecular Weight 
C12H22O11·H2O  360.31 
Structural Formula 
 
Figure 8: Structure of Lactose monohydrate 
Functional Category 
Binding agent; diluent for dry-powder inhalers; tablet binder; tablet and 
capsule diluent. 
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Applications in Pharmaceutical Formulation   
Lactose is widely used as a filler or diluent in tablets and capsules, and to a 
more limited extent in lyophilized products and infant formulas. Lactose is also used 
as a diluent in dry-powder inhalation. Various lactose grades are commercially 
available that have different physical properties such as particle size distribution and 
flow characteristics. This permits the selection of the most suitable material for a 
particular application; for example, the particle size range selected for capsules is 
often dependent on the type of encapsulating machine used. Usually, fine grades of 
lactose are used in the preparation of tablets by the wet-granulation method or when 
milling during processing is carried out, since the fine size permits better mixing with 
other formulation ingredients and utilizes the binder more efficiently. 
Other applications of lactose include use in lyophilized products, where 
lactose is added to freeze-dried solutions to increase plug size and aid cohesion. 
Lactose is also used in combination with sucrose to prepare sugar-coating solutions. 
Direct-compression grades of lactose monohydrate are available as 
granulated/ agglomerated α-lactose monohydrate, containing small amounts of 
anhydrous lactose. 
Direct-compression grades are often used to carry lower quantities of drug and 
this permits tablets to be made without granulation. 
Other directly compressible lactoses are spray-dried lactose and anhydrous 
lactose.  
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Incompatibilities 
A Maillard-type condensation reaction is likely to occur between lactose and 
compounds with a primary amine group to form brown, or yellow-brown-colored 
products. 
Lactose is also incompatible with amino acids, aminophylline, amfetamines, 
and lisinopril. 
 
Lubricant: Magnesium stearate 
Nonproprietary Names 
• BP: Magnesium stearate 
• JP: Magnesium stearate 
• PhEur: Magnesii stearas 
• USPNF: Magnesium stearate 
Synonyms 
Magnesium octadecanoate; octadecanoic acid, magnesium salt; stearic acid, 
magnesium salt. 
Chemical Name and CAS Registry Number 
Octadecanoic acid magnesium salt [557-04-0] 
Empirical Formula and Molecular Weight 
C36H70MgO4, 591.34 
Structural Formula 
[CH3(CH2)16COO]2Mg 
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Functional Category 
Tablet and capsule lubricant. 
Applications in Pharmaceutical Formulation or Technology 
Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5.0% w/w. It is also used in barrier creams. 
Incompatibilities 
Incompatible with strong acids, alkalis, and, iron salts. Avoid mixing with 
strong oxidizing materials. Magnesium stearate cannot be used in products containing 
aspirin, some vitamins, and most alkaloidal salts. 
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EXPERIMENTAL SECTION 
PART - I 
ANALYTICAL METHOD  
USED FOR ESTIMATION OF GLIMEPIRIDE IS UV 
SPECTROPHOTOMETRY 
 
Preparation of 0.1N Hydrochloric acid with 0.5% w/v of Sodium Lauryl 
Sulphate 
8.5ml of concentrated Hydrochloric acid added in 1000ml of distilled water 
under stirring pH was 1.2 and 50g of Sodium Lauryl Sulphate slowly added until to 
complete soluble. 
Standard Graph of Glimepiride in 0.1N HCL with 0.5% w/v SLS 
Stock solution was prepared by 50mg of Glimepiride substance in 100ml 
Methanol. From this stock solution 10ml was withdrawn and diluted up to 100ml 
using 0.1N HCL with 0.5 % w/v SLS. Calibration curve was prepared by using 
different concentration (5µg/ml - 25µg/ml) by appropriate dilution of stock solution. 
The absorbance was measured at 236 nm. [Anju Goyal and I. Singhvi, 2007] and are 
as given in Table 7. 
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RESULTS AND DISCUSSION 
 
The absorbance for various concentrations measured at 236nm is as follows 
Table 7: Standard Graph of Glimepiride in 0.1N HCL with 0.5% w/v SLS 
Sl. 
No. Concentration (µg/ml) Absorbance at 236nm 
1 5 0.2531 
2 10 0.4473 
3 15 0.6205 
4 20 0.8057 
5 25 1.0412 
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Figure 9: Standard Graph of Glimepiride in 0.1N HCL with 0.5% w/v SLS 
Abs = A + B * Conc  
A = 0.0050 
B = 0.0318 
Coefficient  0.999862  
Glimepiride shows good linearity with the range 5 to 25µg with r2 = 0.9998,  
Slope = 0.318, Intercept = 0.0050.  
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PART-II 
 
PRE FORMULATION STUDIES 
 
Drug Polymer Interaction Studies 
 IR Spectroscopy (using IR Spectrophotometer Jasco FT-IR8201 PC by 
KBr Pellet Method) was carried out on pure substances and their physical 
mixtures to search the possible interaction (Glimepiride) [Y.R. Sharma, 2007] 
and various polymers are depicted in figure 10 to 13. 
 
RESULTS AND DISCUSSION 
 
IR Spectra of Pure Drug 
 The IR Spectrum for Glimepiride  in pure form was observed to have 
peaks at [Pyrrole] 3475 cm-1 [C = O] 1670 cm-1 [C – N] 1443 cm-1 [N - H] 3417 cm-1 
[SO2] 1151 cm-1 [N - H] 3285 cm-1 which are shown in figure 10. 
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IR Spectra of Physical Mixture of Glimepiride with Hypromellose 
[K4MCR] 
 The IR Spectra of Glimepiride with HPMC [K4MCR] was observed to 
have peaks at 3261 cm-1, 1387 cm-1, 1583 cm-1, 3265 cm-1, 1303 cm-1, 3513 cm-1 
which are shown in figure 11, which indicates that there is no interaction between 
two. 
 
IR Spectra of Physical Mixture of Glimepiride with Carbopol   
The IR Spectra of Glimepiride with Carbopol was observed to have 
peaks at 3373 cm-1, 1739 cm-1, 1455 cm-1, 3277 cm-1, 1111 cm-1, 3217 cm-1 which 
are shown in figure 12, which indicates that there is no interaction between two. 
 
IR Spectra of Physical Mixture of Glimepiride with Hypromellose 
[K100MCR] 
The IR Spectra of Glimepiride with Hypromellose K100MCR was 
observed to have peaks at 3503 cm-1, 1644 cm-1, 1445 cm-1, 3676 cm-1, 1124 cm-1, 
3157 cm-1 which are shown in figure 13, which indicates that there is no interaction 
between two. 
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PART - III 
Formulation Development 
Direct compressible blend was prepared by using Glimepiride, Lactose 
monohydrate, Hypromellose, Carbopol, and Magnesium stearate along with Sodium 
bicarbonate. This compressible mixture were mixed thoroughly and sifted through   
30 mesh. This compressible blend was then compressed as a tablet by using 7mm 
punch weighing 150 mg. 
Various formulations were compressed by varying the proportion of rate 
controlling polymer (Hypromellose - K4MCR / K100MCR), gel forming polymer 
(Carbopol), as depicted in Table 8. 
Table 8: Composition of tablet formulations 
Ingredients F1 
(mg) 
F2 
(mg) 
F3 
(mg) 
F4 
(mg) 
F5 
(mg) 
F6 
(mg) 
F7 
(mg) 
Glimepiride 4 4 4 4 4 4 4 
Lactose monohydrate 75 65.5 55 65.5 55 35 75 
Sodium bicarbonate 50 50 50 50 50 50 50 
Hypromellose K4MCR 10 19.5 30 10 10 30 -- 
Hypromellose  
K100MCR -- -- -- -- -- -- 10 
Carbopol 934P 10 10 10 19.5 30 30 10 
Magnesium stearate 1 1 1 1 1 1 1 
Tablet weight 150 150 150 150 150 150 150 
% of Gel forming 
Polymer 7 7 7 13 20 20 7 
% of Rate controlling 
polymer 
7 13 20 7 7 20 7 
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PART - IV 
Evaluation of Granules 
A) Angle of Repose 
Flow properties of the granules were evaluated by determining the Angle of 
Repose and the compressibility index. Static angle of repose was measured according to 
the fixed funnel and free standing core method of Banker and Anderson. A funnel with 
the end of the stem cut perpendicular to the axis of symmetry is secured with its top a 
given height (1 cm), h, above graph paper placed on a flat horizontal surface. The 
granules were carefully poured through the funnel until the apex of the conical pile so 
formed just reached the tip of the funnel. Thus, with R being the radius of the base of the 
granules conical pile and the angle of repose was calculated by using the equation 
[Cooper. J and Gunn L., 1986] and are as reported in Table 9. 
tan θ =  h/r 
where θ is the angle of repose.   
 
B) Bulk Density 
Both loose bulk density (LBD) and tapped bulk density (TBD) were determined. 
A suitable amount of powder from each formulation, previously lightly shaken to break 
any agglomerates formed, was introduced into a 10ml measuring cylinder. After initial 
volume was observed, the cylinder was allowed to fall under its own weight on to a hard 
surface from a height of 2.5 cm at 2 seconds intervals. The tapping was continued until 
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no further change in volume was noted. LBD and TBD were calculated using the 
following formula [Shah, et.al. 1999] and are as reported in Table 10. 
LBD = weight of the powder / volume of the packing 
TBD = weight of the powder / tapped volume of the packing 
C) Compressibility Index 
Compressibility index of the powder was determined by Carr’s compressibility 
index [Aulton ME, and Wells, 1988] and are as reported in Table 10. 
Carr’s index (%) = [(TBD – LBD) x 100]/TBD. 
 
RESULTS AND DISCUSSION 
A) Angle of Repose 
The angle of repose for the granules of various formulations F1 to F7 are as given 
in Table 9.  
Table 9: Angle of Repose of granules 
Formulation (n) Angle of Repose (θ) 
F1 23°.62′ 
F2 20°.92′ 
F3 20°.22′ 
F4 21°.03′ 
F5 23°.38′ 
F6 25°.34′ 
F7 25°.97′ 
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Angle of Repose of our precompressed granules was in the range 20º.22´ to 
25º.97´, which indicate that precompressed granules having excellent flow property 
which is in compliance with the angle of repose ≤ 30º as mentioned in the Leon 
Lachman, et.al. 1990. 
B) Bulk Density 
The LBD and TBD, Compressibility index for the granules for various 
formulations F1 to F7 are given in Table 10. 
 
Table 10: Bulk Density and Compressibility index of Granules 
Formulation 
(n) 
Loose Bulk 
Density (g/ml) 
Tapped Bulk 
Density (g/ml) 
Compressibility 
index (%) 
F1 0.482 0.614 21.50 
F2 0.451 0.603 25.21 
F3 0.457 0.614 25.57 
F4 0.468 0.598 21.74 
F5 0.462 0.582 20.62 
F6 0.453 0.543 16.57 
F7 0.442 0.567 22.05 
 
LBD and TBD for all the formulations ranged from 0.442 to 0.482 and 0.543 to 
0.614 respectively. Compressibility Index (%) ranged from 16.57 to 25.57. All the 
formulations exhibited good compressibility index.  
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EVALUATION OF COMPRESSED TABLETS 
 
 Quality control test for Glimepiride compressed tablets (GFDDS) were 
performed as follows. 
1. General Appearance 
The general appearance of tablets, its visual identity and overall ‘elegance’ is 
essential for consumer acceptance for monitoring the production process.  
Size and shape 
The shape and dimensions of compressed tablets are determined by the type of 
tooling during the compression process. 
2. Thickness and diameter 
Ten tablets were measured using vernier caliper. Ten tablets from each 
formulation were used and average value was calculated and as are given in Table 11. 
3. Hardness 
From each batch five tablets were tested using Monsanto Hardness Tester and 
as are given in Table 12.  
4. Friability 
The friability test was performed for all the formulated tablets using Roche 
Friabilator. Ten tablets were taken and their weight was determined (W0) then they 
were placed in a rotating drum. Then they were subjected to 100 revolutions. After 
completion of 100 revolutions or 4 min of time at 25 rpm, the tablets were again 
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weighed (W). The percentage friability (f) was calculated by the formula given and as 
are given in Table 13. 
f = W0 - W / W0  x 100 
5. Weight variation 
For uniformity of weight, twenty tablets from each formulation were selected 
at random. The individual 20 tablets from each batch were determined by using 
electrical balance and as are shown in Table 14. 
6. Content Uniformity 
Each tablet was crushed and transferred to 100 ml volumetric flask. The 
powder was dissolved in 3 ml of methanol and volume made up to 100 ml by 0.1N 
HCL with 0.5% w/v of SLS. The sample solution kept under stirring for 5 minutes 
after that it was filtered through Whatman filter paper. Appropriate dilution of filtered 
solution was done by 0.1N HCL and with 0.5% w/v of SLS. Absorbance of solution 
is measured at 236 nm by UV Spectrophotometer ( BP 2003 )and as are shown in 
Table 15. 
7. Assay  
Weigh and powdered 10 tablets. Weigh accurately a quantity of powder 
equivalent to about 1.5 gm and shake with 100 ml of methanol for 10 minutes. From 
that 10ml taken and diluted up to 100 ml using 0.1N HCL with 0.5% w/v of SLS. The 
sample solution kept under stirring for 5 minutes after that it was filtered through 
Whatman filter paper. Appropriate dilution of filtered solution was done by 0.1N 
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HCL and with 0.5% w/v of SLS. Absorbance of solution is measured at 236nm by 
UV Spectrophotometer and as are shown in Table 16. 
8. In vitro Dissolution Studies 
Dissolution profile was performed using the media containing 0.1N HCL with 
0.5% w/v of Sodium Lauryl Sulphate (SLS). This dissolution test was carried out by 
using USP Apparatus-1 (basket) at 50 rpm, temperature at 37 ± 0.5ºC. 5ml of sample 
was withdrawn and equal volume of dissolution media was replaced at a definite 
intervals and the concentration of drug present in the sample is estimated using UV 
Spectroscopy as mentioned earlier in Part-I. 
The drug release profile for various formulations from F1 to F7 and for the 
marketed sample are as reported below. 
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Drug Release Kinetics 
Method used to compare dissolution data was, 
• Model Dependent Methods in which the dissolution profile of each formulation has 
been subjected various kinetics like zero order, first order, Higuchi’s, Korsmeyer’s 
[Saathoff N, et.al. 1992; Wai-Yip Lee T, et.al. 2000] 
The data obtained from in vitro drug release studies were plotted in various 
kinetic models: as mentioned below zero order (Equation 1) as cumulative amount of 
drug released vs time, first order (Equation 2) as log cumulative percentage of drug 
remaining vs time, and Higuchi’s model (Equation 3) as cumulative percentage of drug 
released vs square root of time. 
C = K0 t                                 (Equation 1) 
where K0 is the zero-order rate constant expressed in units of concentration/time and t is 
the time in hours. A graph of concentration vs time would yield a straight line with a 
slope equal to K0 and intercept the origin of the axes. 
LogC = LogCo−kt/2.303        (Equation 2) 
where C0 is the initial concentration of drug, k is the first order constant, and t is the time. 
Q = Kt ½          (Equation 3) 
where K is the constant reflecting the design variables of the system and t is the time in 
hours. Hence, drug release rate is proportional to the reciprocal of the square root of time.  
Drug release were plotted in Korsmeyer et al’s equation (Equation 4) as log cumulative 
percentage of drug released vs log time, and the exponent n was calculated through the 
slope of the straight line. 
Mt/M∞ = Ktn                      (Equation 4) 
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where Mt/M∞ is the fractional solute release, t is the release time, K is a kinetic 
constant[Hamid A. Merchant, et.al. 2006] and as are shown in figure 16  to 43. 
9) Buoyancy test 
Buoyancy test was carried out in dissolution media [Timmermans and Andre, 
1994] up to 8 hours. 
RESULTS AND DISCUSSION 
1) General Appearance 
The shape of the tablets of all formulation remained circular with no 
visible cracks. 
2) Thickness and Diameter 
The thickness and diameter for the compressed tablets of various 
formulations F1 to F7 are as given in Table 11.  
Table 11: Diameter and Thickness of  Compressed Tablet 
Formulations Diameter (mm) * Thickness (mm) * 
F1 7.05 2.6 ± 0.02 
F2 7.02 2.7 ± 0.03 
F3 7.03 2.5 ± 0.04 
F4 7.05 2.9 ± 0.01 
F5 7.00 2.6 ± 0.03 
F6 7.01 2.6 ± 0.02 
F7 7.02 2.9 ± 0.02 
  * - Average value of 10 tablets 
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All the formulations showed thickness in range of 2.5mm to 2.9mm.  
All the formulations showed diameter in range of 7.01mm to 7.05mm 
which is shown in Table 11. 
3) Hardness 
The hardness test of various formulations F1 to F7 are as given in Table 12. 
 
Table 12: Hardness of Compressed Tablet 
Formulations Hardness Kg/Cm2 
F1 4.7 
F2 4.7 
F3 4.8 
F4 4.7 
F5 4.7 
F6 4.2 
F7 4.5 
 
All the formulations showed reasonably good hardness value of 4.2 to 4.8 
kg/cm2 is given in Table 12. 
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4) Friability 
The friability test of various formulations F1 to F7 are as given in Table 13. 
Table 13: Friability of Compressed Tablets 
Formulations Friability (%) 
F1 0.052 
F2 0.041 
F3 0.040 
F4 0.032 
F5 0.021 
F6 0.011 
F7 0.012 
 
Compressed tablets that lose less than 0.5 to 1.0 % of their weight are 
generally considered acceptable. [Leon Lachman, et.al. 1990] This indicates that 
the tablets can withstand the mechanical shocks reasonably well during handling 
which are shown in Table 13. 
 
5) Weight Variation 
The weight variation test of various formulations F1 to F7 are as given in 
Table 14. 
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Table 14: Weight variation of Compressed Tablets 
Formulations Weight Variation (mg) * 
F1 149.58 ± 0.81 
F2 149.99 ± 0.83 
F3 151.01 ± 0.73 
F4 150.08 ± 0.72 
F5 150.05 ± 0.80 
F6 150.00 ± 0.20 
F7 150.32 ± 0.71 
* - Average value of 20 tablets. 
 
The percentage deviation allowed for a tablet weighing more than 80 mg 
and less than 250 mg ± 7.5% as mentioned in BP 2003. 
The percentage deviation obtained from the various formulations was 
observed within the pharacopoeial limit. 
6) Content Uniformity 
The content uniformity test of various formulations F1 to F7 are given in 
Table 15. 
 
 
 Chapter 8   Evaluation of Compression tablets  
 75
 
Table 15: Content uniformity of Compressed tablets 
Formulations Amount of drug content (%) 
F1 101.32 
F2 98.60 
F3 99.01 
F4 102.13 
F5 108.07 
F6 101.52 
F7 99.33 
 
Content uniformity test revealed that of tablets within the range (80% to 
120%) of pharmacopeial (BP 2003) limit which are shown in the Table 15. 
 Chapter 8   Evaluation of Compression tablets  
 76
7) Assay 
The assay of various formulations F1 to F7 are as given in Table 16. 
 
Table 16: Assay of Compressed tablets 
Formulations Assay (%) 
F1 92.70 
F2 93.89 
F3 101.30 
F4 94.00 
F5 99.06 
F6 91.32 
F7 95.64 
 
The assay revealed that of tablets within the range (95% to 105%) of which are 
shown in the Table 16. 
8. Dissolution 
In vitro dissolution studies of various formulations and marketed sample. 
The dissolution profile of various formulations F1 to F7 and marketed 
formulations are as mentioned below in Table 17 and 18 as depicted in Figure 14 
and 15 respectively. 
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Table 17: In vitro drug release profile data of various formulations 
Percentage of Drug Released Time in 
Hrs F1 F2 F3 F4 F5 F6 F7 
1 32 30 27 17 16 31 19 
2 57 37 45 23 17 56 36 
3 75 50 66 27 21 75 46 
4 93 68 91 33 23 92 53 
5 97 92 93 33 27 97 76 
6 -- -- -- 38 28 -- 79 
7 -- -- -- 45 33 -- 85 
8 -- -- -- 53 54 -- 89 
 
 
Figure 14: In vitro drug release profile data of various formulations 
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In various formulations 92 to 97% of release was observed by the formulations 
F1, F2, F3, and F6 within 5 hours. 89% of release was observed by the formulation F7 up 
to 8 hours, 52 to 55% of release observed by the formulations F4 and F5 up to 8 hours.  
In vitro drug release profile of Marketed Formulation    
 
Table 18: Drug release profile for Marketed Formulation 
Time in minutes % of drug released 
15 54 
30 80 
45 96 
 
 
Figure 15: In vitro drug release profile of Marketed Formulation 
In marketed preparation 96% of release was observed within 45 minutes. 
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Dissolution Kinetics 
 Dissolution Kinetics for Formulation 1 (F1) 
 The dissolution profile of formulation F1 was subjected to various kinetic studies 
and are as depicted in the following figures 16 to 19. 
      
 Figure 16: Zero order release kinetics F1              Figure 17: First order release kinetics F1 
    Figure 18: Higuchi release kinetics F1       
Figure19: Korsmeyer release kinetics F1 
 The release profile exhibiting a maximum ‘r2’ value was found to obey that 
particular kinetics. Hence F1 was found to obey Korsmeyer’s release kinetics. 
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Dissolution Kinetics for Formulation 2 (F2) 
 The dissolution profile of formulation F2 was subjected to various kinetic studies 
and are as depicted in the following figures 20 to 23. 
 
 
 
 
 
 
 
Figure 20: Zero order release kinetics F2             Figure 21: First order release kinetics  
 
 
 
 
 
 
 
FFigure 22: Higuchi release kinetics F2         Figure 23: Korsmeyer release kinetics F2 
The release profile exhibiting a maximum ‘r2’ value was found to obey that 
particular kinetics. Hence F2 was found to obey Zero order release kinetics. 
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Dissolution Kinetics for Formulation 3 (F3) The dissolution profile of 
formulation F3 was subjected to various kinetic studies and are as depicted in the 
following figures 24 to 27. 
Figure 24: Zero order release kinetics F3          Figure 25: First order release kinetics F3 
Figure 26: Higuchi release kinetics F3               Figure 27: Korsmeyer release kinetics F3  
The release profile exhibiting a maximum ‘r2’ value was found to obey that particular 
kinetics. Hence F3 was found to obey Korsmeyer’s order release kinetics. 
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Dissolution Kinetics for Formulation 4 (F4) 
 The dissolution profile of formulation F4 was subjected to various kinetic studies 
and are as depicted in the following figures 28 to 31 
 
Figure 28: Zero order release kinetics F4      Figure 29: First order release kinetics F4 
 
 
Figure 30: Higuchi release kinetics F4      Figure 31: Korsmeyer release kinetics F4 
The release profile exhibiting a maximum ‘r2’ value was found to obey that 
particular kinetics. Hence F4 was found to obey Higuchi release kinetics. 
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Dissolution Kinetics for Formulation 5 (F5) 
 The dissolution profile of formulation F5 was subjected to various kinetic studies 
and are as depicted in the following figures 32 to 35. 
 
 
 
 
 
 
 
 
Figure 32: Zero order release kinetics F5              Figure 33: First order release kinetics F5 
 
Figure 34: Higuchi release kinetics F5              Figure  35: Korsmeyer release kinetics F5 
 
The release profile exhibiting a maximum ‘r2’ value was found to obey that 
particular kinetics. Hence F5 was found to obey Zero order release kinetics. 
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Dissolution Kinetics for Formulation 6 (F6) 
 The dissolution profile of formulation F6 was subjected to various kinetic studies 
and are as depicted in the following figures36 to 39. 
 
    Figure 36: Zero order release kinetics F6              Figure 37: First order release kinetics F6 
 
 
Figure 38: Higuchi release kinetics F6              Figure 39: Korsmeyer release kinetics F6 
The release profile exhibiting a maximum ‘r2’ value was found to obey that 
particular kinetics. Hence F6 was found to obey Korsmeyer’s release kinetics. 
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Dissolution Kinetics for Formulation 7 (F7) 
 The dissolution profile of formulation F7 was subjected to various kinetic studies 
and are as depicted in the following figures 40 to 43. 
 
T 
 
 
 
 
Figure 40: Zero order release kinetics F7             Figure 41: First order release kinetics F7 
 
The release profile exhibiting a maximum ‘r2’ value was found to obey that 
particular kinetics. Hence F7 was found to obey Korsmeyer’s release kinetics. 
  
 
 
 
 
 
 
Figure 42: Higuchi release kinetics F7                Figure 43: Korsmeyer release kinetics F7 
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The release profile of all the formulation, F1 was found to obey Korsmeyer’s 
release kinetics, F2 was found to obey Zero order release kinetics, F3 was found to obey 
Korsmeyer, F4 was found to obey Higuchi, F5 was found to obey Zero order release 
kinetics, F6 was found to obey Korsmeyer’s release kinetics, F7 was found to obey 
Korsmeyer’s release kinetics 
9) Buoyancy test 
The tablet of formulations F1, F2, F3 and F6 buoyant for 5 hours. 
Formulations F4, F5, and F7 remained buoyant for a period of 8 hours and are as 
shown in figure 44 and 45. 
 
 
 
 
 
 
 
 
 
Figure 44: Floating ability of Gastro Retentive Formulation of Glimepiride after 1hr 
 
 
 
 
 
 
 
 
 
Figure 45: Floating ability of Gastro Retentive Formulation of Glimepiride after 8 hrs 
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SUMMARY AND CONCLUSION 
 
Glimepiride is second generation new sulfonyl urea oral antidiabetic. 
Glimepiride is poorly soluble in acidic environment. When it is given orally in 
healthy people, it absorbs rapidly and completely. However, its absorption is erratic 
in diabetic patients due to impaired gastric motility or gastric emptying. This erratic 
absorption of Glimepiride becomes clinically significant, since the efficacy of short 
acting sulfonylurea is dependent upon the absorption rate of the drug. Hence, to 
overcome the above mentioned drawbacks the present study aims to develop 
Glimepiride as Floating Drug Delivery System (FDDS) and its evaluation.  
IR Spectroscopy was carried out on pure substances and their physical 
mixtures to search the possible interaction. The IR Spectrum of pure and physical 
mixture exhibited there is no interaction between the drug and excipients used for 
study. 
Around 7 formulations weighing 150mg  were compressed by varying the 
proportion of rate controlling polymer (Hypromellose - K4MCR / K100MCR), gel 
forming polymer (Carbopol). 
The granules of different formulations were evaluated for angle of repose, 
bulk density, and compressibility index. The result of angle of repose indicates 
reasonably good flow property of granules. The compressibility index values, further 
support flow property of the granules. 
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Compressed tablets of all the formulations were evaluated such as physical 
appearance, thickness and diameter, hardness, friability, weight variation, content 
uniformity, assay and dissolution. The tablets were circular in shape with no visible 
cracks with smooth appearance. All the formulations showed reasonably good 
hardness values. Friability of compressed tablets that lose less than 0.5 to 1% of their 
weight are generally considered acceptable which indicate that all the formulations 
compliance with that of standard. Weight variation test revealed that the tablets were 
within the range of pharmacopeial limit. Content uniformity test compliance that of 
tablets within the range of pharmacopeial limit. Assay was performed using UV 
spectroscopy. 
The In vitro dissolution study was performed for various formulations and 
marketed formulation. Various formulations were subjected to various model 
dependent kinetics like Zero order, Higuchi, Korsmeyer release kinetics. The release 
profile exhibiting maximum r2 value was found to obey that particular kinetics. It was 
observed  F1 was found to obey Korsmeyer’s release kinetics, F2 was found to obey 
Zero order release kinetics, F3 was found to obey Korsmeyer’s release kinetics, F4 
was found to obey Higuchi’s release kinetics, F5 was found to obey Zero order 
release kinetics, F6 was found to obey Korsmeyer’s release kinetics, F7 was found to 
obey Korsmeyer’s release kinetics. 
All the formulations were buoyant, in this formulation F1, F2, F3 and F6 
buoyant for 5 hours. Remaining formulations F4, F5 and F7 were found to  buoyant 
for a period of 8 hours. 
ABBREVIATIONS 
AUC  - Area under curve 
BMI  - Body Mass Index 
CDDS  - Controlled Drug Delivery System 
CL  - Clearance 
Cmax  - Maximum concentration of drug in plasma 
CR  - Controlled Release 
DMF  - Dimethyl Formamide 
ER   - Extended Release 
F  - Bioavailability  
FDDS  - Floating Drug Delivery System 
GRDDS - Gastro Retentive Drug Delivery System  
HBS  - Hydrodynamically Balanced System 
IR  - Infrared  
LBD  - Loose Bulk Density 
NDDS  - Novel Drug Delivery System 
SR  - Sustained Release 
SLS  - Sodium Lauryl Sulphate 
TBD  - Tapped Bulk Density 
T ½   - Biological Half life 
UV  - Ultraviolet Spectroscopy 
Vd  - Volume of Distribution 
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